|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
AUA 2026 Bladder Cancer Program: Focus on BCG-Naive Intensification Trials
|
|
Bogdana Schmidt, MD, MPH
|
| Bogdana Schmidt previews the AUA 2026 bladder cancer program which will spotlight several practice-shaping updates, including BCG-naive intensification data from POTOMAC and PATAPSCO, new results for detalimogene and TLD-1433 in BCG-unresponsive disease, and studies of cretostimogene and UGN-102 durability, as well as Jeremy Teoh’s Latimer Lecture on robotic en-bloc TURBT.
|
|
|
|
|
|
|
|
|
|
|
|
|
AUA 2026 Preview: Perioperative EV/Pembro, ctDNA, and Bladder Preservation
|
|
Petros Grivas, MD, PhD
|
| Petros Grivas previews the AUA 2026 bladder cancer program. A discussion on EV and pembrolizumab moving earlier will include the role of consolidative surgery after deep response in oligometastatic disease. He highlights the newly launched ECOG-ACRIN 8231, a phase 3 trial comparing pembrolizumab plus sacituzumab govitecan with primary growth factor prophylaxis against conventional chemotherapy in patients with prior immunotherapy.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the Upcoming 2026 American Urological Association Annual Meeting
|
|
|
|
|
|
| Plenary: Practice-changing, Paradigm-Shifting Clinical Trials in Urology - 07:30 - 11:45 AM
|
|
|
|
|
Durvalumab with BCG Therapy for High-Risk NMIBC: Expanded Efficacy and Safety Analyses from POTOMAC
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
Topline Results From PIVOT-006- A Phase 3, Randomized Controlled Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for Intermediate-Risk NMIBC
Presented By: Max Kates, MD
|
|
|
|
|
A Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS, with or Without Papillary Disease: Pivotal Phase 2 Interim Results of Detalimogene Voraplasmid
Presented By: Ashish Kamat, MD, MBBS
|
|
|
|
|
Intravenous Pembrolizumab Combined with Intravesical Bacillus Calmette–Guérin (BCG) for Patients with BCG-Naïve “Very High-Risk” T1 Non-Muscle Invasive Bladder Cancer
Presented By: Eugene Pietzak, MD
|
|
|
|
|
Darolutamide plus Androgen Deprivation Therapy (ADT) in mHSPC: ARASEC – US Prospective, Open-Label Phase 2 Study with an External Control
Presented By: Rana McKay, MD
|
|
|
|
|
Long-Term Oncological Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Phase 3 Randomized Controlled Trial
Presented By: Jean Felipe Lestingi, MD
|
|
|
|
|
Extended Follow-up Shows Accumulating Benefit for Patients Treated with CAN-2409+prodrug in Combination with Standard of Care External Beam Radiation (EBRT) in Men with Localized Prostate Cancer
Presented By: Mark Garzotto, MD
|
|
|
|
|
|
|
| IP36: Bladder Cancer: Invasive I - 09:30 - 11:30 AM
|
|
|
|
|
IP36-22: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience
Presented By: Daniel Roberson, MD
|
|
|
|
|
| IP41: Bladder Cancer: Invasive II - 1:00 - 3:00 PM
|
|
|
|
|
IP41-21: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer
Presented By: Michael Jalfon, MD
|
|
|
|
|
|
|
| IP50: Bladder Cancer: Non-Invasive IV - 07:00 - 09:00 AM
|
|
|
|
|
IP50-15: Blue-Light-Guided Transurethral Laser Ablation (TULA) for Non-Muscle-Invasive Bladder Cancer: First UK Single-Centre Experience on Recurrence Free Survival
Presented By: Aaryan Sandhu
|
|
|
|
|
| International Prostate Forum (Neal Shore + ZK Moderating) - 08:00 AM - 12:00 PM
|
|
|
|
|
Prostate Cancer Screening, Detection, and Surveillance - Guidelines vs Real-World Practice vs Recent Evidence
Presented By: Badar Mian, MD
Localized Treatment - The Daily Triage of Grade Group 2 Prostate Cancer
Presented By: John Davis, MD, FACS
Locally Advanced and Recurrent PCa Updates - Debate: Treatment of High-Risk miN1 Prostate Cancer
Presented By: Daniel Spratt, MD, and Giorgio Gandaglia, MD
|
|
|
|
|
|
|
|
|
|
Locally Advanced and Recurrent PCa Updates - Management of Biochemical Recurrence in 2026
Presented By: Karen Hoffman, MD, MHSc, MPH
|
|
|
|
|
Advanced Prostate Cancer - Doublet vs Triplet: Who Needs Additional Treatment Intensification for mHSPC?
Presented By: Jacqueline Brown, MD
|
|
|
|
|
Advanced Prostate Cancer - Toxicities/AEs 101: What to Know for mHSPC Treatment Intensification
Presented By: Kelvin Moses, MD, PhD
|
|
|
|
|
Advanced Prostate Cancer - First-Line mCRPC: How Do I Select the Best Treatment for My Patient?
Presented By: Kristine Lacuna, MD
|
|
|
|
|
Advanced Prostate Cancer: Radioligand Therapy in 2026: When Should We Use Lu-PSMA-617 and What Other Options Are on the Horizon?
Presented By: Phillip Koo, MD
|
|
|
|
|
Beyond First/Second-Line mCRPC Treatment: What's Next?
Presented By: Andrew Hahn, MD and Robert Dreicer, MD
|
|
|
|
|
| PD23: Prostate Cancer: Advanced (Including Drug Therapy) II - 3:30 PM - 5:30 PM
|
|
|
|
|
PD23-02: Prostate-Specific Antigen Endpoints in the Phase 3 PSMAddition Study of [177Lu]Lu-PSMA-617 Combined with ADT and ARPI in Patients with PSMA-Positive (PSMA+) mHSPC)
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
